CVS Health (NYSE:CVS) Given New $92.00 Price Target at Deutsche Bank Aktiengesellschaft

CVS Health (NYSE:CVS) had its price objective hoisted by stock analysts at Deutsche Bank Aktiengesellschaft from $88.00 to $92.00 in a report issued on Thursday, MarketBeat.com reports. The firm currently has a “buy” rating on the pharmacy operator’s stock. Deutsche Bank Aktiengesellschaft’s target price would indicate a potential upside of 4.91% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Barclays reiterated an “overweight” rating and issued a $101.00 price target on shares of CVS Health in a report on Thursday. The Goldman Sachs Group raised their target price on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a report on Thursday, February 12th. Sanford C. Bernstein raised shares of CVS Health from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $91.00 to $94.00 in a research note on Thursday, March 12th. Bank of America reduced their target price on CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a report on Tuesday, January 27th. Finally, HSBC upped their price objective on CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Tuesday. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.20.

CVS Health Trading Up 1.0%

CVS Health stock traded up $0.84 during midday trading on Thursday, hitting $87.70. 563,188 shares of the stock were exchanged, compared to its average volume of 8,423,662. The company has a fifty day simple moving average of $76.60 and a two-hundred day simple moving average of $78.00. The stock has a market capitalization of $112.39 billion, a PE ratio of 63.60, a P/E/G ratio of 0.84 and a beta of 0.60. CVS Health has a 52 week low of $58.35 and a 52 week high of $88.63. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm’s revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts anticipate that CVS Health will post 7.14 EPS for the current fiscal year.

Institutional Investors Weigh In On CVS Health

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Swiss RE Ltd. bought a new position in CVS Health in the 4th quarter valued at about $26,000. Sankala Group LLC bought a new position in shares of CVS Health in the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd boosted its position in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 281 shares during the last quarter. Mcguire Capital Advisors Inc. bought a new stake in CVS Health during the fourth quarter worth $28,000. Finally, Ares Financial Consulting LLC bought a new position in CVS Health during the 4th quarter valued at $29,000. 80.66% of the stock is owned by institutional investors.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q1 beat and guidance raise — CVS posted adjusted EPS of $2.57 and revenue of $100.4B, topping estimates, and raised FY‑2026 adjusted EPS guidance to $7.30–$7.50, signaling better-than-expected operating performance and giving investors more confidence in 2026 earnings. CVS Health raises 2026 forecast after improving medical cost controls
• Positive Sentiment: Insurance turnaround driving profits — CVS reported roughly $2.9B in Q1 net income as Aetna’s medical benefit ratio improved (84.6% vs. 87.3% prior year), easing a prior drag and materially contributing to the beat. That improvement is central to the stock’s strength. CVS Health reports $2.9B in Q1 profit as Aetna strengthens
• Positive Sentiment: Management confidence on margins — Executives said Aetna is on a path to meet Medicare Advantage margin goals by 2028 after five consecutive quarters of improvement, reducing execution risk for the insurance segment. CVS execs say company on track to meet MA margin goals by 2028
• Positive Sentiment: Pharmacy cost initiatives — CVS Caremark will expand biosimilar formulary adoption (effective July 1), which should lower drug costs and support pharmacy margin improvement over time. CVS Caremark Expands Biosimilar Adoption
• Negative Sentiment: Analyst view still cautious — HSBC raised its price target from $83 to $85 but kept a “hold” rating; the PT sits below the stock’s current level, indicating some analysts see limited near-term upside. That dampens how bullish some investors will be despite the beat. HSBC Raises CVS Health Price Target to $85.00

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.